Beam Therapeutics (BEAM) Total Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Total Liabilities data on file, last reported at $316.4 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 7.98% year-over-year to $316.4 million in Q1 2026; TTM through Mar 2026 was $316.4 million, a 7.98% decrease from a year earlier, with the FY2025 full-year figure at $242.8 million, down 34.42% from the prior year.
• Total Liabilities for Q1 2026 stood at $316.4 million, up from $242.8 million in the prior quarter.
• Over the last five years, Total Liabilities for BEAM reached as high as $635.8 million in Q3 2022 and fell as low as $242.8 million in Q4 2025.
• Historically, Total Liabilities has averaged $458.0 million across 5 years, with a median of $446.3 million in 2024.
• Across the five-year window, Total Liabilities soared 130.54% in 2022 and sank 34.42% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $608.2 million in 2022, then retreated by 21.35% to $478.4 million in 2023, then decreased by 22.6% to $370.3 million in 2024, then sank by 34.42% to $242.8 million in 2025, then soared by 30.29% to $316.4 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $316.4 million in Q1 2026, $242.8 million in Q4 2025, and $345.1 million in Q3 2025.